Abeona Therapeutics, Inc. (ABEO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.00+1.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABEO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 5.9% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 94.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ABEO — earnings miss
Dated 2026-08-13
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing.
Why it matters: Making a profit is key for the company's financial health and future growth.
Worry ifNet income rises from -$17.1 million in Q1 2026.
Less concerning ifNet income remains at -$17.1 million or worsens in subsequent quarters.
Why it matters: More treatment centers will help more patients access ZEVASKYN. This will increase its use.
Supportive ifActivation of at least two more QTCs by the end of Q3 2026.
Worry ifNo new QTC activations by the end of Q3 2026, suggesting challenges in expanding the network.
Why it matters: The recent change in officers may change Abeona's strategy. Investors need to watch for news.
Watch forAbeona announces a new executive with a strong track record in biotech.
Also watch forNo new executives have been hired. There are no updates to the strategy.
Why it matters: Higher revenue means ZEVASKYN is selling well. This shows the company is financially healthy.
Supportive ifNet product revenue exceeds $8.7 million in Q2 2026.
Worry ifNet product revenue falls below $8.7 million in Q2 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$194 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $534 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,948 loss on $10,000 · 39.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Watching cash burn helps check if operations can last until they make money.
Worry ifCash burn less than $(19.8) million in Q2 2026.
Less concerning ifCash burn equal to or greater than $(19.8) million in Q2 2026.
Why it matters: More patients using ZEVASKYN shows it is accepted in the market. This affects revenue.
Supportive ifAt least six patients scheduled for ZEVASKYN treatment in Q2 2026.
Worry ifFewer than six patients scheduled for treatment in Q2 2026.
Why it matters: More treatment centers help more patients and support ZEVASKYN's growth.
Supportive ifAt least two new QTCs activated by the end of Q3 2026.
Worry ifNo new QTCs activated by the end of Q3 2026.
Why it matters: Growing revenue shows strong demand for ZEVASKYN. It also supports management's business plan.
Supportive ifIn Q3, ZEVASKYN revenue is over $11.4 million. This shows growth from last quarter.
Worry ifIn Q3, ZEVASKYN revenue is below $11.4 million. This may show problems with demand or supply.
Why it matters: Filing for ABO-701 would mark a key step in expanding Abeona's pipeline and growth potential.
Supportive ifAbeona files an IND application for ABO-701 by the end of 2027.
Worry ifNo IND filing for ABO-701 by the end of 2027, suggesting delays in development.
Why it matters: Earnings results will show if Abeona is moving closer to profitability. A significant loss may raise concerns.
Worry ifQ2 earnings report shows a net income loss less than -$15M.
Less concerning ifNet income loss is over -$15M. This shows financial health is getting worse.
Why it matters: A smaller net loss means better financial health. It shows progress toward making money.
Supportive ifNet loss in Q3 2026 is less than $(20.2) million.
Worry ifIn Q3 2026, the net loss is over $(20.2) million. This shows ongoing financial problems.